2021 began on an encouraging note, with Diagnostics again lending support to the lynchpin Pharmas division – continued to be impacted by biosimilar erosion and/or pandemic disruption. While the group’s near-term outlook still remains jittery – amid the current backdrop of resurfacing COVID-19 risks, growing Diagnostics dominance – backed by near-term tailwinds and long-term potential of innovative offerings in Pharmas – lend ample support to our investment case.

21 Apr 2021
Not bad Q1 21, but patience is still warranted

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Not bad Q1 21, but patience is still warranted
- Published:
21 Apr 2021 -
Author:
Amandeep Goyal -
Pages:
5 -
2021 began on an encouraging note, with Diagnostics again lending support to the lynchpin Pharmas division – continued to be impacted by biosimilar erosion and/or pandemic disruption. While the group’s near-term outlook still remains jittery – amid the current backdrop of resurfacing COVID-19 risks, growing Diagnostics dominance – backed by near-term tailwinds and long-term potential of innovative offerings in Pharmas – lend ample support to our investment case.